

Original Research Article

EFFECT OF FERMENTED *PENTACLETHRA MACROPHYLLA BENTH* (AFRICAN OIL BEAN) SEED EXTRACT ON PLASMA LIPID PROFILE IN HEALTHY RAT MODEL.

ABSTRACT

Background: African oil bean seed is one of several plants products commonly used in Nigeria as food. However, report as to whether or not it could predispose consumers to atherosclerosis as evidenced by alteration in the lipid profile is yet to be documented.

Aim: The study aim was to determine the effect of fermented *Pentaclethra Macrophylla Benth* (African oil bean) seed extract on lipid profiles.

Methods: A total of twenty-five (25) male rats randomly divided into five groups of 5 rats each per group were used. Each group received the crude methanol seed extract of *Pentaclethra Macrophylla Benth* (MEPB) once daily at the dose of 500, 1000, 1500 and 2000 mg kg⁻¹ body weight, respectively for 14 days except the control group. Lipid profile parameters were determined according to enzymatic assay using a commercial kit from Randox Laboratories, United Kingdom and calculation using Friedewald's equation.

Results: A statistically significant increase in HDL and decrease in LDL content ($p < 0.05$) were obtained following the administration of MEPB in all dosed groups compared with the control group. Administration of MEPB in all dosed groups improved lipid metabolism and increased percentage protection against atherogenesis by a range between 61% - 87%.

22 **Conclusion:** Fermented African oil bean seed has a positive effect on lipid metabolism and
23 showed an anti-atherogenic property. According to the result, African oil bean seeds at the level
24 used in the study could protect against atherosclerosis.

25

26 **Key Words:** dyslipidemia, Ukpaka, Lipid profile, atherogenesis, *Pentaclethra Macrophylla*

27 *Benth*

28

29 1. INTRODUCTION

30 Among all people of all places and times, the overlap between nutrition and health has been
31 probably understood, at least to some extent [1, 2]. Many have explored the use of large number
32 of plants products in treatment of diseases as dietary plant products can serve simultaneously as a
33 source of food and therapy [1]. Documented evidence suggests that about 80% of primary
34 healthcare provided in developing countries depend mostly on use of plants products for the
35 treatment of several diseases as they have been shown to be safe with no adverse effects [3,4]. In
36 African, for instance in Nigeria, public promotion of medicinal plants underpins the normative
37 basis for use of plant products in maintenance of health [4]. Besides important phytochemical
38 components that adapt dietary plant products for pharmacological actions, every plant product
39 including African oil bean seeds, possesses important nutrients and biochemical such as protein,
40 fat, vitamins, minerals and carbohydrate which are essential for metabolic functions [4,36].

41 The African Oil bean seed (*Pentaclethra macrophylla Benth*), is produced by large woody plant
42 (family Leguminosae Mimosoidae) which is native to tropical Africa [36]. The hard but smooth
43 flat brown seeds are contained in a long flattened green pod. It becomes edible after processing
44 and fermentation [5,36]. Locally, particularly among the South Eastern part of Nigeria where it is

45 popularly regarded as the “African Salad”, it is known as “Ugba” or Ukpaka” which is a very
46 important delicacy in the life of South Eastern Nigerians. However, due to increase in integration
47 and change in food habit, the “African Salad” as it is called is increasingly gaining popularity
48 across every region in Nigeria [6]. African oil bean seed contains phyto-nutrients, including
49 alkaloids, saponins, flavonoids, and tannins [7,36], as such have been reported to be effective in
50 the treatment of diarrhoea and anaemia while the pod and leaf extracts are used in the treatment
51 of convulsion [5,6,36]. Some dietary/medicinal plants have been shown to alter normal body
52 chemistry which invariably affects normal function of some organs in the body [8]. Fermented
53 African oil bean seed (AOBS) is one of several plants products commonly used in Nigeria as
54 food. However, report as to whether or not it could predispose consumers to atherosclerosis and
55 its associated coronary heart disease evidenced by alteration in the lipid profile is yet to be
56 documented. Given the paucity of report on its effect on lipid profile in consumers of AOBS
57 (ukpaka), the present study was undertaken to investigate the effect of crude methanol extract
58 of the fermented African oil bean seeds (ukpaka) on lipid profile using a healthy rat model .

59

60 **2. MATERIALS AND METHODS**

61 **2.1. Collection and authentication of plant material**

62 Fresh samples of fermented slices of *Pentaclethra Macrophylla Benth* seeds (Ukpaka) were
63 purchased from Obeleagu Umana in Ezeagu , Enugu state, Nigeria. The plant material was
64 authenticated by a consultant taxonomist at the herbarium section of the Department of Plant
65 Science and Biotechnology, University of Nigeria, Nsukka and a voucher specimen deposited at
66 the herbarium for future reference.

67 **2.2. Processing of *Pentaclethra Macrophylla Benth* seeds powder**

68 The fermented slices of *Pentaclethra Macrophylla Benth* seeds were dried under the shade at
69 room temperature. The dried seeds were milled with an electric blender and finally ground into
70 powder using a hammer mill (500# grinder/Fuyu Metal, Linyi Fuyu Metal Products Co., Ltd,
71 China) and thereafter, passed through 52 mm sieve (Turgens and Co., Germany).

72

73 **2.3 Chemicals and Reagents**

74 The kits for, triglycerides, total cholesterol and HDL-Cholesterol were also purchased from
75 Randox Laboratory United Kingdom. All the other reagents and chemicals of analytical grade
76 were obtained from research laboratories in Enugu.

77 **2.4 Preparation of the crude methanol extract**

78 The powdered seeds (1500 g) of *pentaclethra macrophylla benth* seeds powder was weighed out,
79 placed in a gallon, and 2.5 liters of absolute methanol added and left for 48hrs. The mixture,
80 intermittently, was agitated during the extraction process. After 48hrs, the mixture was sieved
81 using muslin cloth and filtered with a Whatman No. 1 filter paper and the filtrate then evaporated
82 to dryness on a rotary evaporator (Model 349/2 Corning Ltd,England). The oily liquid residue
83 obtained was stored in a refrigerator at $4 \pm 2^{\circ}\text{C}$ until required. This was labelled the methanol
84 crude extract (MEPB).

85 **2.5 Determination of Extractive Value for the crude methanol extract**

86 The concentration of the crude methanol extract was determined by weighing the total oily liquid
87 residue in electronic weighing balance and the density calculated which is expressed in mg/ml.
88 The appropriate concentration then was calculated for the study.

89 **2.6 Experimental Animals**

90 **2.6.1 Animal Housing and Management**

91 Twenty -five (25) apparently healthy albino rats of same sex and age between 150g and 170g
92 body weight were obtained from Animal House of the College of Medicine, University of
93 Nigeria Teaching Hospital, Enugu. They were acclimatized for a period of two (2) weeks in
94 clean gauzed cages in groups of five (5) according to their body weight under good laboratory
95 conditions at the Animal House of the College of Medicine, University of Nigeria, Enugu
96 campus. The rats had free access to food (commercial standard pellets, Topfeed^R Nigeria) and
97 clean water daily.

98 **2.6.2 Acute toxicity (Median Lethal Dose, LD50)**

99 The median lethal dose (LD₅₀) of fermented African oil bean seeds [AOBS] was calculated to be
100 > 6000 mg/kg body weight using the standard procedures as described by Lorke [9].

101 **2.6.3 Experimental Design**

102 **Animal Grouping and Extract Administration**

103 A total of twenty-five (25) male rats were randomly grouped into five: A, B, C, D and E of 5
104 animals each per group after being allowed to acclimatize for 2 weeks. Rats in groups B, C, D
105 and E were administered with the methanol seed extract (MEPB) once daily at the dose of 500,

106 1000, 1500 and 2000 mg kg⁻¹ body weight, respectively for 14 days. Group A (control), were
107 treated just like the test groups except that the animals received only water instead of the seed
108 extract. The methanol extract was administered to all animals in the different groups using oral
109 gavage technique. The extract and distilled water were administered daily at the same point time
110 throughout the duration of the experiment. The animals were allowed free access to rat pellets
111 and tap water after the daily doses.

112 **Sub-acute Study and Collection of Blood from Animals**

113 The sub- acute study began with an oral administration of the extract every morning for 14 days.
114 On the 15th day, following overnight fast, the animals was bled through the median canthus of
115 the eye under ether anaesthesia using capillary tubes. Blood sample was collected into plain
116 tubes and separated from cells to assay for lipid profile.

117 **2.7 Ethical approval**

118 Handling, management and use of animals for the experiment was such that allowed minimal
119 stress according to the international Guidelines on experiments involving the use of animals laid
120 down in “Ethical and Scientific Considerations Regarding Animal Testing and Research”[42].
121 The study was approved by the Animal House of the College of Medicine, University of Nigeria
122 Teaching Hospital, Enugu.

123 **2.8 Biochemical Analyses**

124 Measurement of serum lipid profile

125 Triglycerides and total cholesterol were estimated using enzymatic colorimetric methods as
126 described by Fossati & Prencipe [10] and Fredrickson et al., [40] respectively. High density

127 lipoprotein (HDL) was measured enzymatic ally after all non HDL lipoproteins were removed
128 [41]. LDL-C was calculated using Friedewald's equation: $LDL = \text{total cholesterol} - [\text{HDL} +$
129 $(\text{TG}/5)]$. Atherogenic Index (AI) = $(\text{Total cholesterol} - \text{HDL cholesterol}) / \text{HDL cholesterol}$.
130 $\text{Protection \%} = \text{AI (control)} - \text{AI (treated)} / \text{AI (control)} \times 100$ [11].

131 **2.9 Data analysis**

132 All data were analyzed using SPSS software (version 22) and results expressed as mean \pm SEM.
133 One way analysis of variance (ANOVA) followed by Post hoc multiple comparison tests was
134 used to compare difference in means among the groups. $P < 0.05$ was considered to be
135 statistically significant value.

136 **3. RESULTS**

137 There was significant increase ($p < 0.05$) in the serum High-Density Lipoprotein Cholesterol
138 (HDL-C) content following the administration of the methanol seed extract in all the dose
139 groups; B (56.60 ± 3.31 mg/dl), C (63.00 ± 5.03 mg/dl), D (56.50 ± 2.36 mg/dl), and E ($32.40 \pm$
140 4.37 mg/dl) when compared with the control group A (13.20 ± 3.31 mg/dl) (Table 1). Serum
141 Low-Density Lipoprotein Cholesterol (LDL-C) content following the administration of the
142 methanol seed extract in all the dose groups; B (20.32 ± 7.55 mg/dl), C (18.16 ± 3.02 mg/dl), D
143 (24.30 ± 6.02 mg/dl), and E (41.44 ± 8.43 mg/dl) when compared with the control group A
144 (44.64 ± 6.71 mg/dl) showed a significant decrease ($p < 0.05$), (Table 1). However, T.CHOL, T.G
145 and VLDL do not differ significantly when compared with those of control group respectively (p
146 > 0.05). There were significant reductions in the atherogenic index in all dose groups with a
147 percentage protection between 61% - 87% as opposed to the control group A. (Table 2).

148

149 **Table 1: Mean and standard error of mean of the biochemical parameters**

GROUP	T.CHOL mg/dl)	T.G (mg/dl)	HDL (mg/dl)	VLDL(mg/dl)	LDL mg/dl)
A-CONTROL	81.00±9.38	92.60±6.86	13.20±3.31	18.52±1.37	44.64±6.71
B-500 mg/bwt	96.00±7.92	90.20±10.41	56.60±3.94 ^{a,b}	19.08±2.94	20.32±7.55 ^a
C-1000 mg/bwt	98.40±4.13	86.20±10.72	63.00±5.03 ^{a,c}	17.24±2.14	18.16±3.02 ^a
D- 1500 mg/bwt	96.25±5.28	89.75±8.59	56.50±2.36 ^{a,d}	17.95±1.72	24.30±6.02 ^a
E-2000 mg/bwt	91.80±8.74	89.20±3.39	32.40±4.37 ^a	17.84±0.67	41.44±8.43
F-ratio	0.66	0.12	21.14	0.16	2.94
P-value	0.68	0.99	0.00*	0.99	0.03*

150 (*) significant difference, $P = .05$; bwt= body weight151 a = ($P = .05$) when compared with the control group A.152 b, c, d= ($P = .05$) when compared with group E.

153

154

155

156 **Table 2: Atherogenic index (AI) of methanol seed extract of *Pentaclethra Macrophylla***157 ***Benth***

GROUP	T.CHOL(mg/dl)	HDL(mg/dl)	AI	% Protection
A-CONTROL	81.00±9.38	13.20±3.31	5.2*	-
B-500 mg/bwt	96.00±7.92	56.60±3.94	0.7	87
C-1000 mg/bwt	98.40±4.13	63.00±5.03	0.5	90
D- 1500 mg/bwt	96.25±5.28	56.50±2.36	0.7	87
E-2000 mg/bwt	91.80±8.74	32.40±4.37	2.0	61

158 * $P = .05$ when control is compared with other groups

159

160

161 4. DISCUSSION

162 This study showed a significant increase in HDL-C following the administration of
163 African oil bean seeds (AOBS) extract. Although, the mechanism by which HDL-C increased is
164 not completely understood; however, AOBS may have influenced a variety of molecules
165 involved in HDL metabolism, and the Reverse cholesterol transport (RCT) system. The first
166 speculation involved in HDL increase may be attributed to increase in the amount of ApoA-1
167 level in the liver which is a main component protein of HDL [12-16]. ATP-binding cassette
168 transporter A1 (ABCA1) in the hepatocytes which transports cholesterol within cells to Apo A-1
169 forming pre- β HDL [17, 18], may have leveraged on the phyto-nutrients of AOBS to drive the
170 increase in HDL fraction. Secondly, HDL containing reduced level of phospholipids is prone to
171 decomposition and is easily metabolized by endothelial lipase (EL). EL is one of the factors
172 promoting HDL catabolism due to its phospholipase activity and the ability to hydrolyse
173 phospholipid in HDL particles [19-21]. Thus, it is speculative that the extract may have
174 decreased the serum endothelial lipase (EL) mass or activity thereby decreasing the HDL
175 catabolism [22]. Therefore, inhibition of EL activity by the extract may have resulted in the
176 elevated level of HDL. The result is in agreement with previous studies done by other
177 researchers [23-28], who reported increase in HDL-C levels with dietary plants products.
178 Inhibition of cholesteryl ester transfer protein (CETP) which regulates the transfer of cholesterol
179 ester from HDL to other fractions of plasma cholesterol [39] is another mechanism that could
180 explain this. As such, HDL fraction may have been elevated through the inhibition of CETP by
181 AOBS extract.

182 The increase in HDL fraction is clinically significant in maintenance of good
183 cardiovascular health, in that increase in the concentration of HDL-C have been demonstrated to

184 correlate inversely with coronary heart diseases [29-32]. HDL-C transports cholesterol from
185 peripheral tissues to the liver for metabolism and excretion thereby decreasing the amount stored
186 in the tissue and the possibility of developing atherosclerotic plaques. As such, HDL-Cholesterol
187 is considered to possess anti-atherogenic properties, and hence regarded as the good cholesterol
188 [33,34].

189 Following the administration of AOBS extract, result also showed a significant decrease in
190 low-density lipoprotein cholesterol (LDL-C) level. African oil bean seeds contain phytochemical
191 components such as saponins that can reduce cholesterol levels [35]. The precise mechanism of
192 action of the extract, in relation to reduction in LDL-C fraction, was not elucidated in this work.
193 However, AOBS may have contributed to the inhibition of lipid absorption from the gut due to
194 the presence of saponins and tannins in the extract [35]. The significant decrease in serum LDL-
195 C is quite understandable since an increase in serum total cholesterol could be an indirect effect
196 of the increase in serum HDL-C [36]. LDL-C act as the primary transporter of plasma cholesterol
197 to peripheral tissue through the arterial walls which may build up, forming plaques with
198 progression to atherosclerosis and increasing the risk of high blood pressure and stroke [37],
199 therefore is considered the bad cholesterol. The decreased LDL fraction observed in the study
200 suggests that, consumption of AOBS is not associated with dyslipidemia, which constitute a
201 major risk factor for development of cardiovascular diseases, particularly atherosclerosis [38].
202 Atherogenic index (AI) [ratio of LDL-cholesterol to HDL-cholesterol] is a normative predictor
203 of cardiovascular risk [39] with an index of greater than 5 set as the cut-offs for high risk of
204 atherosclerosis [11]. Following the extract administration, the values for AI for all dosed groups
205 were less than 5. This indicates that the extract improved lipid metabolism and increased
206 percentage protection against atherogenesis by a range between 61% - 87%. This is suggestive

207 that fermented African oil beans seed (AOBS) is not linked with any positive risk for
208 atherogenesis, hence may not predispose to heart diseases.

209

210 5. CONCLUSION

211 Taken together, the study demonstrated that fermented African oil beans seed (ukpaka) has a
212 good anti-atherogenic potential evidenced by the reduction in AI as shown from the increase in
213 the concentrations of HDL-C fraction and decrease in LDL-C fractions. Therefore, consumption
214 of fermented African oil bean seeds could potentially reduce cardiovascular risk and prevent
215 atherosclerotic process because of elevated HDL content of the serum lipid observed.

216

217

218 REFERENCES

- 219 1. Zhang,L., Zhang,Y., Pei,S., Geng,Y., Wang,C.& Yuhua,W. Ethnobotanical survey of
220 medicinal dietary plants used by the Naxi People in Lijiang Area, Northwest Yunnan,
221 China. *Journal of Ethnobiology and Ethnomedicine*, 2015;11:. 40
- 222
- 223 2. Leonti, M. Herbal teas and the continuum of the food-medicine complex: field methods,
224 contextualisation and cultural consensus. *Journal of Ethnobiology and*
225 *Ethnomedicine*,2014;151:1028–1030
- 226
- 227 3. WHO. Regulatory situation of herbal medicines: a worldwide review. World Health
228 Organization, Geneva, Switzerland,2013.
- 229
- 230 4.Beyene,B., Beyene,B.& Deribe,H. Review on Application and Management of Medicinal
231 Plants for the Livelihood of the Local Community. *Journal of Resources Development and*
232 *Management*,2016; 22:33-39.
- 233
- 234
- 235 5.Cangao,C. African Indigenous Fruit with Potential Health Benefits. International Tropical
236 Fruits Network [online], 2011. Available from: < <http://www.itfnet.org/v1/2011/12/african-indigenous-fruits-with-potential-health-benefits/>> [Accessed 22 March 2017].
237

- 238
239
240 6. Nwanjo,H., Iroagba,I., Nnatuanya,I.& Eze,N. Is Fermented Pentactethra Macrophylla
241 Nutritional Or Antinutritional?: Response From Haematological Studies In Protein
242 Malnourished Guinea Pigs. *The Internet Journal of Nutrition and Wellness*,2006;4(2):np.
243
244
245 7. Okwu, D. & Aluwuo, C. Studies on the phytochemical composition and fermentation of the
246 seed of African oil bean tree *pentactethra macrophylla* Benth, *International Journal of*
247 *Chemical Societies*,2008; 6 (2):773-788.
248
249
250 8. Visavadiya, N. & Narasimacharya,A. Hypolipidemic and antioxidant activities of *Asparagus*
251 *racemosus* in hypercholesterolamic rats. *Indian Journal of Pharmacology*,2005; 37: 376-
252 380.
253
254 9. Lorke, D. A new approach to practical acute toxicity testing. *Archives in Toxicology*, 1983;
255 53: 275-289
256
257 10. Fossati, R.& Prencipe, L.Serum triglycerides determined colorimetrically with an enzyme that
258 produces hydrogen peroxide. *Clin Chem*,1982; 28(10):2077-2080.
259
260 11. Ng, T., The, C., Vidyadaran,M., Tee,E., Thong,M., Kandiah,M. & Ehalid,A. A critical
261 evaluation of high density lipoprotein cholesterol as an index of coronary artery disease
262 risk in Malaysians. *American Journal of Clinical Nutrition*,1997;3:61-70.
263
264 12. Teramoto, T., Saito, Y., Yamada, N., Italcura, H., Hata, Y., Nakaya, N., Mabuchi, H.,
265 Sasaki, J., Ogawa, N. & Goto, Y. Clinical safety and efficacy of NK-104 (Pitavastatin) in
266 the long term treatment of hyperlipidemia: results of a multicenter long-term study.
267 *Journal of Clinical Therapeutics in Medicine*,2001;17: 885-914.
268
269 13. Sasaki, J., Ikeda, Y., Kuribayashi, T., Kajiwara, K., Biro, S., Yaruanioro, K., Ageta, M.,
270 Kobori, S., Saikawa, T., Otonari, T.& Kono, S. A 52-week, randomized, open-label,
271 parallel-group comparison of the tolerability and effects of pitavastatin and arorvastatin
272 on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese
273 patients with elevated levels of low-density lipoprotein cholesterol and glucose
274 intolerance. *Clinical Therapeutics*,2008; 30:1089-1101.
275
276 14. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J,
277 Glincur C, Staels B. Starin-induced inhibition of the Rho-signaling pathway activates
278 PPARAlpha and induces HDL apolipoprotein A-I. *Journal of Clinical Investigation*,2001;
279 107: 1423-1432.
280
281 15. Walsh, A., Y. Ito, and .1. L. Breslow. High levels of human apolipoprotein A-I in transgenic
282 mice result in increased plasma levels of small high density lipoprotein (HDL) particles
283 comparable to human HDL3. *Journal of Biological Chemistry*, 1988;264:6488-6494.
284

- 285 16. Eisenberg, S. High density lipoprotein metabolism. *Journal of Lipid Research*,1984;
286 25:1017-1058.
287
- 288 17. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Effect of
289 pitavastatin on apolipo-protein A-I production in HepG2 cell. *Biochemical and*
290 *Biophysical Research Communications*, 2004;324: 839.
291
- 292 18. Ando H, Tsuruoka S, Yatnamoto H, Takamura T, Kaneko S, Fujimura A. Effects of
293 pravastatin on the expression of ATP-binding cassette transporter A1. *Journal of*
294 *Pharmacology and Experimental Therapeutics*, 2004;311: 420-425.
295
- 296 19. Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, South V, Amin D,
297 Perrone M, Rader D. A novel endothelial-derived lipase that modulates HDL metabolism.
298 *Nature Genetics*,1999: 21: 424-428.
299
- 300 20. Hirata, K., Dichek, H., Cioffi, J., Choi, S., Leeper, N., Quintana, L., Kronmal, G., Cooper,
301 A. & Quertermous, T. Cloning of a unique lipase from endothelial cells extends the lipase
302 gene family. *The Journal Biological Chemistry*,1999; 274: 14170- 14175.
303
- 304 21. McCoy, M., Sun, G., Marchadier, D., Maugeais, C., Glick, J. & Rader, D. Characterization of
305 the lipolytic activity of endothelial lipase. *Journal of Lipid Research*, 2002;43: 921-929.
306
- 307 22. Kojima, Y., Ishida, T., Sun, L., Yasuda, T., Toh, R., Rikitake, Y., Fukuda, A., Kume, N.,
308 Koshiyama, H., Taniguchi, A. & Hirata, K. Pitavastatin decreases the expression of
309 endothelial lipase both in vitro and in vivo. *Cardiovascular Research*,2010.
310
- 311 23. Gordon, D. J., and B. M. Rilkind. High-density lipoprotein. The clinical implications of
312 recent studies. *New England Journal of Medicine*, 1989;321:1311-1316.
313
- 314 24. Schaefer, E. , Levy,R., Ernst,N., Van Sant,F., & Brewer,H. The effects of low cholesterol,
315 high polyunsaturated fat, and low fat diets on plasma lipid and lipoprotein cholesterol
316 levels in normal and hypercholesterolemic subjects. *American Journal of Clinical.*
317 *Nutrition*,1981; 34:1758-1763.
318
319
- 320 25. Blum, C., Levy,R., Eisenberg,S., Hall,M.,. Goebel,R.& Berman,M. High density lipoprotein
321 metabolism in man. *Journal of Clinical Investigation*, 1977;60:795-807.
322
- 323 26. Shepherd, J., Packard,C. & Patsch,K. Effects of dietary polyunsaturated and saturated fat on
324 the properties of high density lipoproteins and metabolism of apolipoprotein A-I. *Journal*
325 *of Clinical Investigation*, 1978;61:1582-1592.
326
- 327 27. Zanni, E., Zannis,V., Blum,C., Herbert,P. & Breslow,J. Effect of egg cholesterol and dietary
328 fats on plasma lipids, lipoproteins, and apoproteins of normal women consuming natural
329 diets. *Journal of Lipid Research*, 1987;28:518-527.
330

- 331
332
333 28. Brinton, E., Eisenberg,S. &. Breslow,L. A low-fat diet decreases high density lipoprotein
334 (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rateg. *Journal of*
335 *Clinical Investigation*, 1990;85:144-151.
336
337
338 29. Mayes, P., Murray, R., Granner,D., MayesP. & Rodwell,V. Lipid Transport and Storage. In:
339 Harper's Biochemistry, (24th Edition) Prentice Hall International: USA,1996; 254-255.
340
341
342 30. Castelli, W. Cholesterol and lipids in the risk of coronary artery disease--the Framingham
343 Heart Study. *Canadian Journal of Cardiology*,1988; 4(SA):5a-10a.
344
345
346 31. Gordon, D. , Knoke, J., Probstleld,J., Superko, R.& Tyroler,H.(1986) High. density
347 lipoprotein cholesterol and coronary heart diseaie in hypercholesterolemic men: the lipid
348 research clinics coronary primary prevention trial. *Circulation*,1986; 74:1217-1225.
349
350 32. Miller, N. Associations of high-density lipoprotein subclasses and apolipoproteins with
351 ischemic heart disease and coronary atherosclerosis. *American Heart Journal*,
352 1987;113:589-597.
353
354 33. Brewer, R.High-density lipoproteins: a new potential therapeutic target for the prevention of
355 cardiovascular disease. *Arteriosclerosis, Thrombosis and Vascular Biology*,2004; 24:
356 387-391.
357
358 34. Singh, I., Shishehbor ,M. & Ansell, B. High-density lipoprotein as a therapeutic target: a
359 systematic review. *The Journal of the American Medical Association*, 2007;298: 786-
360 798.
361
362 35.Balogun, B.Evaluation of the Nutritional Potentials of Fermented Oil Beans Seed Pentaclethra
363 macrophyllah Benth. *Production Agriculture and Technology*,2013; 9 (2):73-87.
364
365 36. Woo, K., Chook,P., Chan,L., Cheung, A. & Fungw, H. Long term improvement in
366 homocysteine levels and arterial endonthelial function after 1 year folic acid
367 supplementation. *American Journal of Medicine*, 2002;7: 535-539.
368
369 37. National Research Council. Diet and Health: Implication for Reducing Chronic Disease
370 Risks [online]. Washington DC: National Academic Press,1989. Available from: <
371 <https://www.ncbi.nlm.nih.gov/pubmed/25032333> > [Accessed 20 December 2016]
372
373 38 Raquel, A., Cruz, O., José, L., López,C., Gustavo, A., Aguilar,G., García,H., Gorinstein,S.,
374 Romero,R. & Sánchez,M. Influence of Sorghum Kafirin on Serum Lipid Profile and
375 Antioxidant Activity in Hyperlipidemic Rats (*In Vitro* and *In Vivo* Studies). *BioMed*
376 *Research International*,2015;1-8

- 377
378
379 39. Panagiotakos, B., Pitsavos,C., Skoumas,J., ChrysohoouC., Toutouza,M., C.I. Stefanadis,C. &
380 Toutouzas,P. Importance of LDL/HDL ratio as a predictor for coronary heart disease
381 events in patients with heterozygous familial hypercholesterolemia: A 15 year follow-up
382 (1987-2002). *Current Medical Research and Opinion*, 2003;19: 89-94.
383
- 384 40. Fredrickson, D., Levy, R. & Lees, R. Fat transport in lipoprotein- an integrated approach to
385 mechanisms and disorders. *N Engl J Med*, 1967;276(5):273–281.
- 386 41. Albers, J., Warnick, G.& Chenng, M. Quantitation of high density lipoproteins. *Lipids*,1978;
387 13(12):926–932.
- 388 42. Ferdowsian,H.R, and N. Beck, N. “Ethical and scientific considerations regarding animal
389 testing and research,” *PLoS ONE*, 2011; 6(9).